A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

PHASE1CompletedINTERVENTIONAL

Enrollment

335

Participants

Timeline

Start Date

October 26, 2011

Primary Completion Date

March 12, 2013

Study Completion Date

March 12, 2013

Conditions

Cancer

Interventions

DRUG

GSK1120212

MEK inhibitor

DRUG

GSK2110183

AKT inhibitor

Trial Locations (2)

GSK Investigational Site, Dallas

GSK Investigational Site, San Antonio